Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Recombinant Human Thrombopoietin (rhTPO) in Management of Chemotherapy-induced Thrombocytopenia in Acute Myelocytic Leukemia: a Multicenter Clinical Trial

NCT02244658 is registered in ClinicalTrials.gov with Shandong University as lead sponsor.

NCT NCT02244658
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02244658 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Recombinant Human Thrombopoietin (rhTPO) in Management of Chemotherapy-induced Thrombocytopenia in Acute Myelocytic Leukemia: a Multicenter Clinical Trial
Lead sponsor
Shandong University
Phase
Phase 3
Overall status
Unknown status
Start date
September 30, 2014
Completion date
August 31, 2017
Enrollment
80 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myelocytic leukemia, antineoplastic adverse reaction, thrombocytopenia